|
|
Post by uvula on Jun 3, 2018 20:21:26 GMT -5
|
|
|
|
Post by mango on Jun 3, 2018 21:10:10 GMT -5
United Therapeutics' subsidiary
|
|
|
|
Post by mango on Jun 3, 2018 21:12:04 GMT -5
|
|
|
|
Post by uvula on Jun 3, 2018 21:17:04 GMT -5
So they wanted to recruit 240 people but were only able to recruit 1 person? Something doesn't add up.
|
|
|
|
Post by brotherm1 on Jun 3, 2018 21:20:13 GMT -5
United Therapeutics version: www.tyvaso.com/hcp/Might need a holster and a license to carry permit. |
|
|
|
Post by mango on Jun 4, 2018 1:53:55 GMT -5
So they wanted to recruit 240 people but were only able to recruit 1 person? Something doesn't add up. It ended up not happening. The study results, "Insufficient enrollment, therefore no participants were analyzed." |
|
|
|
Post by #NoMoreNeedles on Jun 4, 2018 3:37:09 GMT -5
According to Mike the TS technology is completely different, as well as the device used and the trial.
|
|
|
|
Post by uvula on Jun 4, 2018 7:55:35 GMT -5
I'm sure the mnkd inhaler is better than the coffeemaker maker sized monster the other company has. But both companies are using treprostinil and it is inhaled so I would guess they are equally effective.
Maybe the other company could buy the mnkd version and it could fund the afrezza runway with no dilution.
|
|
|
|
Post by mnholdem on Jun 4, 2018 8:53:22 GMT -5
|
|
|
|
Post by mannmade on Jun 4, 2018 9:31:42 GMT -5
It is my understanding mike has said it is a $6b market and so even with a 10% market share we are good... imho.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jun 4, 2018 10:43:00 GMT -5
I'm sure the mnkd inhaler is better than the coffeemaker maker sized monster the other company has. But both companies are using treprostinil and it is inhaled so I would guess they are equally effective. Maybe the other company could buy the mnkd version and it could fund the afrezza runway with no dilution. I think there's a play on words here. Tyvaso is more of a Nebulizer that has to be administered 4-7x a day for a person with PAH. Due to dosage limitations the patient cannot get enough medicine into the lungs. Hopefully MNKD can change that with a couple of HITS a day with their DREAMBOAT Inhaler. Their lives will be improve tremendously just like a T1 taking MDIs. UT has partnered with a small biotech company to provide a pump like device that sits on the patients waste to release medicine throughout the day but it doesn't seem to be very convenient. |
|
|
|
Post by mango on Jun 4, 2018 11:12:01 GMT -5
It is my understanding mike has said it is a $6b market and so even with a 10% market share we are good... imho. ~ 45% market share  MannKind's Trep will easily become Standard of Care. mnkd.proboards.com/post/131196/thread |
|
|
|
Post by tiberious on Jun 4, 2018 12:34:30 GMT -5
According to Mike the TS technology is completely different, as well as the device used and the trial. TS / inhaler combo deliver TS and API into the DEEP lung at which point the API (monomeric Insulin, TrpT, etc) is released onto the surface of the lung tissue as tissue PH dissolves the carrier and the medicine passes into bloodstream. Inert carrier molecule is eliminated.
Nebulizers are far less efficient and put a bunch of medicine in the back of the throat etc.
Completely different.
|
|
|
|
Post by uvula on Jun 4, 2018 13:13:09 GMT -5
You would think a company that specializes in this stuff would be interested in licensing mnkd technology since it sounds like a much better solution.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jun 4, 2018 14:32:12 GMT -5
You would think a company that specializes in this stuff would be interested in licensing mnkd technology since it sounds like a much better solution. It's not proven yet. No one will pay millions until they see a pathway for approval. Once TrepT goes into Phase 3 - suitors will start sniffing. Once there's a mid term readout the real discussions will start. I'm expecting that will be around late 2019 or early 2020. I'm not expecting approval until 2021. It seems all projections are pushed back. |
|
